Elotuzumab plus bortezomib and dexamethasone (EBd) versus bortezomib and dexamethasone (Bd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM)-2-year follow-up

Autores de IIS La Fe

• 

  Javier De La Rubia Comos

  Autor

Participantes ajenos a IIS La Fe

• Palumbo, A
• Offidani, M
• Pegourie, B
• Garderet, L
• Laribi, K
• Bosi, A
• Marasca, R
• Laubach, J
• Mohrbacher, A
• Carella, AM
• Singhal, AK
• Lynch, M
• Jou, YM
• Jakubowiak, A

Grupos

• Hematología y Hemoterapia

Abstract

Abstract no disponible